Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
The receipt of CE IVD certification under the EU Medical Devices Directive would green-light the commercialisation of the product in the European Union.
Sales of PeproStat can be as high as US$500mln believes Ergomed
The company’s technology will be used to accelerate the “discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines”.
David Allmond has been brought in from Aegerion Pharmaceuticals, where he worked with the recently in-licensed Lojuxta
The study is examining the effectiveness of its nano-medicine NBTXR3 in patients with soft tissue sarcoma, a cancer found in muscle and fatty areas.
The company is partnering with F Lima, which supplies consumer brands to supermarkets and pharmacies.
"We are pleased to have carried the strong momentum from the first half of 2016 through to the end of the calendar year, continuing to make significant progress across all areas of the business,” said chief executive Doug Doerfler.
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.
A look at some City analysts view on Tuesday.